Axovia’s lead program AXV101 is an adeno-associated virus (AAV9)-based investigational gene therapy that aims to slow down or ...

The Massachusetts based biotech will now press ahead with human trials for its antisense oligonucleotide (ASO) therapy, ...

Josh Gissing is Cluster Head (UK, Ireland & Nordics) for Biocon Biologics: a biosimilars company whose business model seeks ...

The French biotech company Nanobiotix announced today that it has dosed the first patient in the CONVERGE study, a Phase 2 ...

The Swedish biotech hopes its precision therapy will help patients with advanced solid tumors who currently have few ...

As Director of R&D at Sunflower Therapeutics, Laura Crowell works with a team developing biologic medicines and vaccines. She ...

Diane Lacroix, Vice President of Clinical Data Management at eClinical Solutions, talks personalised medicine, data decisions ...

The oversubscribed Series C financing round will support the clinical development of in vivo CAR-T cells for oncology and ...

The US gene therapy company Regenxbio and the Japanese firm Nippon Shinyaku have joined forces to boost the development and ...

The US biotech aims to bring its antibody-based therapies to human trials later in the year and to develop new candidate ...

Orbis Medicines secures €90M Series A to develop innovative oral macrocycles, offering cost-effective alternatives to ...

Following a positive meeting with the FDA, BrainChild is getting ready to initiate a pivotal registration trial with its lead ...